Agent for treatment of metabolic bone disease

Details Agent for treatment of metabolic bone disease Agent for treatment of metabolic bone disease

2007-06-26

2007-06-26

Allen, Marianne P. (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S395000

Reexamination Certificate

active

10516688

ABSTRACT:
An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.

REFERENCES:
patent: 2002/0061849 (2002-05-01), Nielsen et al.
patent: 0 499 242 (1992-08-01), None
Abendroth et al. Erythropoietin enhances histomorphometric signs of renal osteodystrophy. Bone (1997) vol. 20, No. 4 Suppl., pp. 83S. Abstract. Meeting Info: 25th European Symposium on Calcified Tissues. Harrogate, England, UK. (Apr. 25-29, 1997).
Imazeki, et al, “Rapidly progressive renal failure model rat induced by adenine diet”. J. Am. Soc. Nephrol. (2001). 12: A4267.
Koeda, et al, “Early changes of proximal tubles in the kidney of adenine-ingesting rats, with special reference to biochemical and electron microscopic studies”. Japanese Journal of Nephrology. (1988). 30(3):239-246.
Moriguchi, et al, “Rapidly progressive secondary hyperparathyroidism due too renal failure in rats induced by adenine diet”. J. Am. Soc. Nephrol. (2001) 12: A4301.
Mundy, G.R., “Factors which stimulate bone growth in vivo”. Growth Regulation. (1993). 3:124-128.
Okada, et al, “Effect of rHuEPO on bone mineral density (BMD)”. Proceedings of the 9thCongress on Kidney and Erythropoietin Study. (Oct. 28, 2000). Tokyo. pp. 37-41.
Yokazawa, et al, “Animal model of adenine-induced chronic renal failure in rats”. Nephron. (1986). 44:230-234.
Yokozawa, et al, “Adenine-induced hyperuricemia and renal damage in rats”. Nippon Nogeikagaku Kaishi (1982). 56(8):655-663.

Affiliated with

Also associated with

Rating

Agent for treatment of metabolic bone disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for treatment of metabolic bone disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for treatment of metabolic bone disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3824985